Overview
Indications
Gemfibrozil Tablets are indicated as adjunctive therapy to diet for: 1. Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2,000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who con
Contraindications
When this intervention should not be used
Hepatic or severe renal dysfunction, including primary biliary cirrhosis. WARNINGS Preexisting gallbladder disease (see). Hypersensitivity to gemfibrozil. WARNINGS PRECAUTIONS Combination therapy of gemfibrozil with simvastatin (seeand). PRECAUTIONS Combination therapy of gemfibrozil with repaglinid
Indications & Related Conditions
Conditions associated via SNOMED clinical relationships
Administration & Protocol
Dosing, route, and treatment protocol
Detailed dosage and administration information is available in the full FDA drug label.
View full prescribing information on DailyMedMonitoring & Follow-Up
Biomarkers relevant to this intervention via related conditions
No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.
Clinical Trials
20 trials linked to this intervention
Recent Trials
Evaluation of Efficacy and Safety of Omacor (Omega-3-acid Ethyl Esters) as Add-on Therapy in Hypertriglyceridemic Subjects Treated With Antara (Fenofibrate) Followed by an 8-week Extension
Niacin, N-3 Fatty Acids and Insulin Resistance
Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients
Effect of Plant Sterols Esterified to Fish Oil Fatty Acids on Plasma Lipid Levels
Effect of Rosuvastatin on Triglyceride Levels in Mexican Hypertriglyceridemic Patients
Research Evidence
Published studies and systematic reviews
Research data from MEDLINE/PubMed
Benefits & Expected Outcomes
Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.
Risks & Side Effects
Adverse reaction and safety data for this drug is sourced from the FDA-approved label.
View adverse reactions & drug interactions on DailyMedRelated Symptoms
Symptoms associated with conditions this intervention addresses
No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.
Alternatives & Comparisons
Alternative treatments, comparison data, and clinical decision support are pending physician authorship.
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.
Do not start, stop, or change any treatment without consulting your healthcare provider.
Quick Facts
- Type
- Substance / Medication
- Fully Specified Name
- Gemfibrozil (substance)
- SNOMED CT
- 387189002
- UMLS CUI
- C0017245
- RxNorm CUI
- 4719
- Labeler
- REMEDYREPACK INC.
Clinical Data
This intervention maps to 4 entities in the Ltrl knowledge graph.
Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.